AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9668868 — intervention group
Group type: COMPARATOR
Intervention: Education-only program
Number of subjects: 59
Study 8071246 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 224
Study 8071246 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 224
Study 8071246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 2739756 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg (R,S)-propranolol.HCl
Number of subjects: 24
Study 2739756 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg (S)-propranolol.HCl
Number of subjects: 24
Study 2739756 — intervention group
Group type: COMPARATOR
Intervention: 40 mg (R)-propranolol.HCl
Number of subjects: 24
Study 2739756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 4885307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage anticoagulants (36 hours of heparin administration and phenindione at 72 mg/day)
Number of subjects: 1427
Study 4885307 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage anticoagulants (1-mg tablets of phenindione)
Number of subjects: 1427
Study 4885307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage anticoagulants
Number of subjects: 1427
Study 4885307 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage anticoagulants
Number of subjects: 1427
Study 31926484 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver provided 15-20 min daily of developmentally appropriate motor activities
Number of subjects: 99
Study 31926484 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 99
Study 29651600 — intervention group
Group type: EXPERIMENTAL
Intervention: Client self-report quality-of-care scale
Number of subjects: 658
Study 29651600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician self-report quality-of-care scale
Number of subjects: 658
Study 29651600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both client and clinician scales
Number of subjects: 658
Study 28304290 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion recognition rehabilitation and cognitive stimulation therapy (CST)
Number of subjects: 36
Study 28304290 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST)
Number of subjects: 36
Study 28304290 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36
Study 28304290 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion recognition rehabilitation
Number of subjects: 36
Study 27125141 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs (2 million/kg body weight) administered through IV and IM injection
Number of subjects: 11
Study 27125141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UC-MSCs)
Number of subjects: 11
Study 23625592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 113
Study 23625592 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 113
Study 21927687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 130
Study 21927687 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous saline)
Number of subjects: 130
Study 19632048 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 150 microg BID
Number of subjects: 266
Study 19632048 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 225 microg BID
Number of subjects: 266
Study 19632048 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 300 microg BID
Number of subjects: 266
Study 19632048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 16763657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilenticular IOL implantation
Number of subjects: 40
Study 16763657 — intervention group
Group type: COMPARATOR
Intervention: ACCC and PCCC with anterior vitrectomy
Number of subjects: 40
Study 15205127 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 25
Study 15205127 — intervention group
Group type: COMPARATOR
Intervention: FSE-FLAIR and EPI-SE T2-weighted MR sequences
Number of subjects: 25
Study 15205127 — intervention group
Group type: COMPARATOR
Intervention: EPI-GRE T2*-weighted MR sequence
Number of subjects: 25
Study 15205127 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 25
Study 11691758 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health promotion programme
Number of subjects: 634
Study 9270637 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy (cisplatin 70 mg/m2 and vindesine 3 mg/m2)
Number of subjects: 205
Study 9270637 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 205
Study 8164503 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sublingual buprenorphine administration (4 mg/70 kg and 8 mg/70 kg)
Number of subjects: 13
Study 8164503 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day buprenorphine administration (twice the daily maintenance dose every other day)
Number of subjects: 13
Study 3291941 — intervention group
Group type: EXPERIMENTAL
Intervention: D-timolol (0.25%, 0.5%, 1.0%, and 2.0%)
Number of subjects: 30
Study 3291941 — intervention group
Group type: EXPERIMENTAL
Intervention: L-timolol (0.25%)
Number of subjects: 30
Study 3291941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30704424 — intervention group
Group type: EXPERIMENTAL
Intervention: myCompass intervention (self-guided, fully automated)
Number of subjects: 837
Study 30704424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 837
Study 28271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma omega-3 docosapentaenoic acid (DPA)
Number of subjects: 120
Study 28271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha linolenic acid
Number of subjects: 120
Study 28271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma eicosapentaenoic acid
Number of subjects: 120
Study 28271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma docosahexaenoic acid
Number of subjects: 120
Study 26699167 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g in one dose)
Number of subjects: 567
Study 26699167 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 567
Study 23179647 — intervention group
Group type: EXPERIMENTAL
Intervention: Curette first followed by inflatable bone tamps (CF)
Number of subjects: 112
Study 23179647 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflatable bone tamps first followed by curettage and a second IBT inflation (IBTF)
Number of subjects: 112
Study 23179647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 23179647 — intervention group
Group type: EXPERIMENTAL
Intervention: IBTF group
Number of subjects: 112
Study 21251084 — intervention group
Group type: COMPARATOR
Intervention: Plastic occlusion stress test followed by measurement of transepidermal water loss (TEWL) desorption curves
Number of subjects: 0
Study 18464887 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 92
Study 18464887 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 92
Study 22130404 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Sprint Training (FST)
Number of subjects: 27
Study 22130404 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training (RST)
Number of subjects: 27
Study 22130404 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics Training (PT)
Number of subjects: 27
Study 22130404 — intervention group
Group type: COMPARATOR
Intervention: All groups (FST, RST, PT)
Number of subjects: 27
Study 15913878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration
Number of subjects: 30
Study 15913878 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (Control)
Number of subjects: 30
Study 14986682 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 252
Study 14986682 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 252
Study 14986682 — intervention group
Group type: COMPARATOR
Intervention: Memantine + Donepezil
Number of subjects: 252
Study 14986682 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Donepezil
Number of subjects: 252
Study 9934897 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2 mg)
Number of subjects: 43
Study 9934897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9934897 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 43
Study 2179282 — intervention group
Group type: EXPERIMENTAL
Intervention: CR/ZOK formulation of metoprolol (100 mg od, increased to 200 mg od for nonresponders)
Number of subjects: 100
Study 2179282 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets (50 mg bid, increased to 100 mg bid for nonresponders)
Number of subjects: 100
Study 2179282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 6933163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% SnF2 mouthrinse (250 ppmF‐) used twice daily for 5 days
Number of subjects: 29
Study 6933163 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse used twice daily for 5 days
Number of subjects: 29
Study 29719944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter, smaller football (INT, N.=12 teams)
Number of subjects: 346
Study 29719944 — intervention group
Group type: COMPARATOR
Intervention: Traditional FIFA size 5 football (CON, N.=14 teams)
Number of subjects: 346
Study 27517842 — intervention group
Group type: EXPERIMENTAL
Intervention: IV opioid initiated within 60 min
Number of subjects: 204
Study 27517842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial opioid dose (mg/kg/hr of morphine equivalents)
Number of subjects: 204
Study 27517842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial opioid doses (6 mg vs -2.2 mg)
Number of subjects: 204
Study 27517842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioids initiated within 24 hr
Number of subjects: 204
Study 24457421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n=10)
Number of subjects: 18
Study 24457421 — intervention group
Group type: COMPARATOR
Intervention: Sedentary attention control group (n=8)
Number of subjects: 18
Study 24457421 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 18
Study 22484992 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - with counselor training
Number of subjects: 44
Study 22484992 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI) - developing action plans for promotion and free access
Number of subjects: 44
Study 22484992 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 44
Study 22484992 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 44
Study 20147878 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary biopsychosocial rehabilitation program (12-week program, 73 hours of therapist exposure)
Number of subjects: 286
Study 20147878 — intervention group
Group type: COMPARATOR
Intervention: Intensive individual therapist-assisted back muscle strengthening exercises (12-week program, 24 hours of therapist exposure)
Number of subjects: 286
Study 20147878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 286
Study 18384675 — intervention group
Group type: EXPERIMENTAL
Intervention: EASYcare-based Dementia Training Program (DTP) consisting of two workshops, a coaching program, access to an internet forum, and a Computerized Clinical Decision Support System on dementia diagnostics.
Number of subjects: 100
Study 18384675 — intervention group
Group type: COMPARATOR
Intervention: Control group (1/3 of the participants).
Number of subjects: 100
Study 18384675 — intervention group
Group type: EXPERIMENTAL
Intervention: EASYcare-based Dementia Training Program (DTP)
Number of subjects: 100
Study 16603964 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in normotensive controls
Number of subjects: 38
Study 16603964 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in hypertensive patients
Number of subjects: 38
Study 16603964 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg) in both groups
Number of subjects: 38
Study 16603964 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA effect on RCF
Number of subjects: 38
Study 16603964 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional area of CRA
Number of subjects: 38
Study 14662591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% rimexolone
Number of subjects: 54
Study 14662591 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.1% fluorometholone
Number of subjects: 54
Study 11712421 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase, heparin, and aspirin (Group B)
Number of subjects: 29
Study 11712421 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and aspirin (Group A)
Number of subjects: 29
Study 11712421 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 29
Study 9120105 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial flow rate
Number of subjects: 11
Study 1477610 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate (n = 6)
Number of subjects: 12
Study 1477610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 6486521 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting quinidine
Number of subjects: 21
Study 6486521 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting quinidine
Number of subjects: 21
Study 6486521 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine therapy (both short-acting and long-acting)
Number of subjects: 21
Study 31468412 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplement (TG)
Number of subjects: 46
Study 31468412 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine and lotus seeds supplement (TLG)
Number of subjects: 46
Study 31468412 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study 29360622 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN-2017 risk stratification system
Number of subjects: 0
Study 29360622 — intervention group
Group type: COMPARATOR
Intervention: ELN-2010 risk stratification system
Number of subjects: 0
Study 26467048 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplements
Number of subjects: 48
Study 26467048 — intervention group
Group type: COMPARATOR
Intervention: Reference food (glucose beverage)
Number of subjects: 48
Study 25062111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 25062111 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 25062111 — intervention group
Group type: COMPARATOR
Intervention: Urban US neonates
Number of subjects: 0
Study 25062111 — intervention group
Group type: COMPARATOR
Intervention: European neonates
Number of subjects: 0
Study 22467902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 1502
Study 22467902 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 1502
Study 22467902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of patients reporting either menopausal symptoms or arthralgia/myalgia
Number of subjects: 1502
Study 22467902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not reporting symptoms)
Number of subjects: 1502
Study 20043248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound A
Number of subjects: 28
Study 20043248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound B
Number of subjects: 28
Study 20043248 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 28
Study 20043248 — intervention group
Group type: COMPARATOR
Intervention: Washout
Number of subjects: 28
Study 20043248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound A and Sound B
Number of subjects: 28
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective housing stability
Number of subjects: 493
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective housing stability
Number of subjects: 493
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive housing
Number of subjects: 493
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of residences in the last 6 months
Number of subjects: 493
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing services needs
Number of subjects: 493
Study 17828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in housing status
Number of subjects: 493
Study 16122590 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week postoperative follow-up appointment
Number of subjects: 48
Study 16122590 — intervention group
Group type: COMPARATOR
Intervention: No follow-up
Number of subjects: 48
Study 12090962 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CASI (in-home self-administered audio computer assisted self interview)
Number of subjects: 223
Study 12090962 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 223
Study 12090962 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CASI and Telephone interview
Number of subjects: 223
Study 10517211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 542
Study 10517211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 7670449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate supplementation (ASP)
Number of subjects: 12
Study 7670449 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 12
Study 2175354 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril at 75 mg/day
Number of subjects: 42
Study 2175354 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol at 100 mg/day
Number of subjects: 42
Study 2175354 — intervention group
Group type: EXPERIMENTAL
Intervention: canrenoate potassium at 200 mg/day
Number of subjects: 42
Study 2175354 — intervention group
Group type: COMPARATOR
Intervention: combined group of atenolol and captopril responders (n = 22)
Number of subjects: 42
Study 7030750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg x 4 (Group 1)
Number of subjects: 30
Study 7030750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg x 4 (Group 2)
Number of subjects: 30
Study 7030750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg x 4 (Group 3)
Number of subjects: 30
Study 7030750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (all groups)
Number of subjects: 30
Study 7030750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Groups 2 and 3)
Number of subjects: 30
Study 30991240 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive functional exercises including deep breathing and lower limb motions
Number of subjects: 132
Study 30991240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 132
Study 30991240 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise
Number of subjects: 132
Study 30170597 — intervention group
Group type: EXPERIMENTAL
Intervention: Osurnia (terbinafine, florfenicol, betamethasone)
Number of subjects: 284
Study 30170597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 284
Study 30170597 — intervention group
Group type: EXPERIMENTAL
Intervention: Osurnia
Number of subjects: 284
Study 30170597 — intervention group
Group type: COMPARATOR
Intervention: Osurnia and Placebo
Number of subjects: 284
Study 26577867 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based condition (VC)
Number of subjects: 2100
Study 26577867 — intervention group
Group type: COMPARATOR
Intervention: Text-based condition (TC)
Number of subjects: 2100
Study 24255159 — intervention group
Group type: EXPERIMENTAL
Intervention: Small hood
Number of subjects: 16
Study 24255159 — intervention group
Group type: COMPARATOR
Intervention: Large hood
Number of subjects: 16
Study 24255159 — intervention group
Group type: COMPARATOR
Intervention: Small hood and Large hood
Number of subjects: 16
Study 22068817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen according to ATP‐CRA (Group B)
Number of subjects: 63
Study 22068817 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen (Group A)
Number of subjects: 63
Study 20082342 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP education program
Number of subjects: 287
Study 17414675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg a day
Number of subjects: 101
Study 17414675 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg a day
Number of subjects: 101
Study 16343099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 weeks
Number of subjects: 19
Study 11882828 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microg/kg)
Number of subjects: 100
Study 11882828 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (10 mg/kg loading dose followed by 1 mg.kg(‐1).h(‐1) for 12 hours)
Number of subjects: 100
Study 11835848 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow wavelength laser therapy
Number of subjects: 89
Study 11835848 — intervention group
Group type: COMPARATOR
Intervention: Red wavelength laser therapy
Number of subjects: 89
Study 11835848 — intervention group
Group type: COMPARATOR
Intervention: Green wavelength laser therapy
Number of subjects: 89
Study 8949573 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 40
Study 8949573 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 40
Study 8949573 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH+GHRP-2
Number of subjects: 40
Study 8949573 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH+GHRP-2 + TRH
Number of subjects: 40
Study 2022012 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (162.5 mg) + Argatroban (1 micrograms/kg/min)
Number of subjects: 6